Funding Round
Neurona Therapeutics raises $60M Series C ahead of interneuron cell therapy Phase 2
STAT News3/19/2026·03/19/26🇺🇸 USA
Summary
South San Francisco-based Neurona Therapeutics closed a $60M Series C led by Perceptive Advisors, with NEA and Amgen Ventures. Follows positive 12-month Phase 1 safety data showing zero serious adverse events in 6 drug-resistant epilepsy patients. Funds support Phase 2 efficacy expansion and manufacturing scale-up for NRTX-1001 cell therapy.
Why it matters
Clean Phase 1 safety data with Perceptive leading the C-round — they specialize in late clinical and commercial-stage biotech — signals that the market views Neurona as having derisked enough to attract return-oriented capital rather than purely exploratory VC.
#Epilepsy#Industry#Phase 2#USA#Venture Capital
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in